AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 7807033 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study 1778219 — intervention group
Group type: EXPERIMENTAL
Intervention: Medium-chain triglyceride (MCT)/LCT emulsion (Lipofundin MCT 20%)
Number of subjects: 6
Study 1778219 — intervention group
Group type: COMPARATOR
Intervention: Long-chain triglyceride (LCT) fat emulsion (Intralipid 20%)
Number of subjects: 6
Study 6168121 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg Gutron twice daily
Number of subjects: 20
Study 6168121 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 31675922 — intervention group
Group type: EXPERIMENTAL
Intervention: New diagnostic criteria for GDM (2013 WHO criteria)
Number of subjects: 2
Study 31675922 — intervention group
Group type: COMPARATOR
Intervention: Old diagnostic criteria for GDM
Number of subjects: 2
Study 28396242 — intervention group
Group type: EXPERIMENTAL
Intervention: Corticosteroid plus lidocaine
Number of subjects: 400
Study 28396242 — intervention group
Group type: COMPARATOR
Intervention: Lidocaine alone
Number of subjects: 400
Study 25985241 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D3 supplementation (7000 IU/d)
Number of subjects: 44
Study 25985241 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D3 supplementation (4000 IU/d)
Number of subjects: 44
Study 22941193 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium bicarbonate (NaHCO(3)) 0.3 g kg(‐1)
Number of subjects: 12
Study 21459941 — intervention group
Group type: EXPERIMENTAL
Intervention: Milnacipran 200 mg/day (MLN200:MLN200)
Number of subjects: 468
Study 21459941 — intervention group
Group type: COMPARATOR
Intervention: Milnacipran 150 mg/day (PBO:MLN150)
Number of subjects: 468
Study 21459941 — intervention group
Group type: COMPARATOR
Intervention: Milnacipran 100 mg/day (PBO:MLN100)
Number of subjects: 468
Study 21459941 — intervention group
Group type: COMPARATOR
Intervention: Milnacipran 200 mg/day (PBO:MLN200)
Number of subjects: 468
Study 18304542 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin 2,000 mg/day
Number of subjects: 63
Study 18304542 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 63
Study 17929538 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin
Number of subjects: 89
Study 17929538 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 89
Study 15153259 — intervention group
Group type: EXPERIMENTAL
Intervention: Mediterranean‐type diet
Number of subjects: 212
Study 15153259 — intervention group
Group type: COMPARATOR
Intervention: Low-fat/cholesterol diet
Number of subjects: 212
Study 11510873 — intervention group
Group type: EXPERIMENTAL
Intervention: Low intensity handgrip exercise (25% of maximum voluntary contraction)
Number of subjects: 28
Study 11510873 — intervention group
Group type: EXPERIMENTAL
Intervention: High intensity handgrip exercise (75% of maximum voluntary contraction)
Number of subjects: 28
Study 9647682 — intervention group
Group type: EXPERIMENTAL
Intervention: Object-to-position-assignment condition
Number of subjects: 40
Study 9647682 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined condition
Number of subjects: 40
Study 9647682 — intervention group
Group type: EXPERIMENTAL
Intervention: Positional reconstruction
Number of subjects: 40
Study 9647682 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual task during encoding with concurrent articulatory suppression
Number of subjects: 40
Study 7972347 — intervention group
Group type: EXPERIMENTAL
Intervention: Brofaromine 50 mg/day
Number of subjects: 47
Study 7972347 — intervention group
Group type: EXPERIMENTAL
Intervention: Brofaromine 100 mg/day
Number of subjects: 47
Study 7972347 — intervention group
Group type: EXPERIMENTAL
Intervention: Brofaromine 150 mg/day
Number of subjects: 47
Study 7972347 — intervention group
Group type: COMPARATOR
Intervention: Tranylcypromine 20 mg/day
Number of subjects: 47
Study 2661738 — intervention group
Group type: EXPERIMENTAL
Intervention: BCNU alone
Number of subjects: 571
Study 2661738 — intervention group
Group type: EXPERIMENTAL
Intervention: Alternating courses of BCNU and procarbazine
Number of subjects: 571
Study 2661738 — intervention group
Group type: EXPERIMENTAL
Intervention: BCNU plus hydroxyurea alternating with procarbazine plus VM‐26
Number of subjects: 571
Study 2661738 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole-brain irradiation (6020 rads) concurrent with chemotherapy
Number of subjects: 571
Study 2661738 — intervention group
Group type: COMPARATOR
Intervention: Whole-brain radiotherapy (4300 rads) plus coned down boost (1720 rads)
Number of subjects: 571
Study 31250043 — intervention group
Group type: EXPERIMENTAL
Intervention: Antiretroviral Therapy (ART)
Number of subjects: 44
Study 28681424 — intervention group
Group type: EXPERIMENTAL
Intervention: Protected Engagement Time (PET) wards
Number of subjects: 10
Study 28681424 — intervention group
Group type: COMPARATOR
Intervention: Non-PET wards
Number of subjects: 10
Study 28681424 — intervention group
Group type: EXPERIMENTAL
Intervention: Both PET and Non-PET wards
Number of subjects: 10
Study 26821769 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 kg/mg ketamine
Number of subjects: 48
Study 26821769 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.2 kg/mg ketamine
Number of subjects: 48
Study 26821769 — intervention group
Group type: COMPARATOR
Intervention: normal saline (NS)
Number of subjects: 48
Study 26821769 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups (A, B, C)
Number of subjects: 48
Study 26821769 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 kg/mg ketamine and 0.2 kg/mg ketamine
Number of subjects: 48
Study 24627208 — intervention group
Group type: EXPERIMENTAL
Intervention: Relevant training regimen (T1 practice for both paradigms)
Number of subjects: 0
Study 24627208 — intervention group
Group type: EXPERIMENTAL
Intervention: Irrelevant training regimen (comparable sensorimotor training)
Number of subjects: 0
Study 24627208 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual-search training regimen (Exp. 2 only)
Number of subjects: 0
Study 24627208 — intervention group
Group type: COMPARATOR
Intervention: No-training control group
Number of subjects: 0
Study 21934534 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal estradiol gel (1 g/day)
Number of subjects: 150
Study 21934534 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral estradiol (2 mg/day)
Number of subjects: 150
Study 21934534 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral estradiol combined with medroxyprogesterone acetate (MPA; 5 mg/day)
Number of subjects: 150
Study 21934534 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 150
Study 20738047 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetes screening during pregnancy
Number of subjects: 0
Study 20738047 — intervention group
Group type: COMPARATOR
Intervention: No routine screening
Number of subjects: 0
Study 18632657 — intervention group
Group type: EXPERIMENTAL
Intervention: TA haplotype (codons 486 and 1822)
Number of subjects: 1399
Study 18632657 — intervention group
Group type: EXPERIMENTAL
Intervention: TT-AA diplotype (codons 486 and 1822)
Number of subjects: 1399
Study 18632657 — intervention group
Group type: COMPARATOR
Intervention: Common SNPs at codons 486, 1678, 1822, 1960, and 2502
Number of subjects: 1399
Study 18632657 — intervention group
Group type: COMPARATOR
Intervention: Advanced metachronous lesions
Number of subjects: 1399
Study 16212580 — intervention group
Group type: EXPERIMENTAL
Intervention: Open flap debridement (OFD)
Number of subjects: 15
Study 16212580 — intervention group
Group type: COMPARATOR
Intervention: Gingivectomy (GV)
Number of subjects: 15
Study 11513771 — intervention group
Group type: EXPERIMENTAL
Intervention: Lichtenstein tension‐free hernioplasty (LH) using polypropylene prosthetic materials
Number of subjects: 35
Study 11513771 — intervention group
Group type: COMPARATOR
Intervention: Conventional Bassini hernia (BH) repair
Number of subjects: 35
Study 9441137 — intervention group
Group type: EXPERIMENTAL
Intervention: Auto-CPAP
Number of subjects: 25
Study 9441137 — intervention group
Group type: COMPARATOR
Intervention: Conventional CPAP
Number of subjects: 25
Study 8487512 — intervention group
Group type: EXPERIMENTAL
Intervention: Health-related fitness classroom instruction (exposed to health fitness topics on a one or two day per week basis)
Number of subjects: 90
Study 8487512 — intervention group
Group type: COMPARATOR
Intervention: Control group (engaged strictly in skill activities daily)
Number of subjects: 90
Study 3695656 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-completion of MHIQ
Number of subjects: 96
Study 3695656 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone interview of MHIQ
Number of subjects: 96
Study 3695656 — intervention group
Group type: EXPERIMENTAL
Intervention: Personal interview of MHIQ
Number of subjects: 96
Study 3695656 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-completion, telephone interview, or personal interview of MHIQ
Number of subjects: 96
Study 3695656 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical function scores
Number of subjects: 96
Study 3695656 — intervention group
Group type: EXPERIMENTAL
Intervention: Social and emotional function scores
Number of subjects: 96
Study 2689375 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypnotic relaxation
Number of subjects: 45
Study 2689375 — intervention group
Group type: COMPARATOR
Intervention: Stimulus control
Number of subjects: 45
Study 2689375 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 45
Study 31958526 — intervention group
Group type: EXPERIMENTAL
Intervention: Lido/Epi:NaHCO3 mixing ratio 3:1 (IMP1)
Number of subjects: 48
Study 31958526 — intervention group
Group type: EXPERIMENTAL
Intervention: Lido/Epi:NaHCO3 mixing ratio 9:1 (IMP2)
Number of subjects: 48
Study 31958526 — intervention group
Group type: EXPERIMENTAL
Intervention: Unbuffered Lido/Epi (IMP3)
Number of subjects: 48
Study 31958526 — intervention group
Group type: COMPARATOR
Intervention: NaCl 0.9% (IMP4, placebo)
Number of subjects: 48
Study 30571543 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of pyridostigmine 60 mg and atomoxetine 18 mg
Number of subjects: 12
Study 30571543 — intervention group
Group type: COMPARATOR
Intervention: Atomoxetine 18 mg
Number of subjects: 12
Study 30571543 — intervention group
Group type: COMPARATOR
Intervention: Pyridostigmine 60 mg
Number of subjects: 12
Study 30571543 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 27863845 — intervention group
Group type: EXPERIMENTAL
Intervention: Monthly ranibizumab
Number of subjects: 60
Study 27863845 — intervention group
Group type: EXPERIMENTAL
Intervention: TREX ranibizumab
Number of subjects: 60
Study 27863845 — intervention group
Group type: COMPARATOR
Intervention: Control fellow eyes
Number of subjects: 60
Study 27863845 — intervention group
Group type: EXPERIMENTAL
Intervention: Monthly ranibizumab (among patients with baseline MA)
Number of subjects: 60
Study 27863845 — intervention group
Group type: EXPERIMENTAL
Intervention: TREX ranibizumab (among patients with baseline MA)
Number of subjects: 60
Study 27863845 — intervention group
Group type: COMPARATOR
Intervention: Control fellow eyes (among patients with baseline MA)
Number of subjects: 60
Study 27863845 — intervention group
Group type: EXPERIMENTAL
Intervention: Incidence of new MA development
Number of subjects: 60
Study 27863845 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline FCT and SHRM thickness
Number of subjects: 60
Study 26049922 — intervention group
Group type: EXPERIMENTAL
Intervention: Trimetazidine (35 mg twice daily)
Number of subjects: 56
Study 26049922 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranolazine (375 mg twice daily for 4 weeks, then 500 mg twice daily)
Number of subjects: 56
Study 23193211 — intervention group
Group type: EXPERIMENTAL
Intervention: 9 dispersed boluses of 2 IU
Number of subjects: 12
Study 23193211 — intervention group
Group type: COMPARATOR
Intervention: 1 bolus of 18 IU
Number of subjects: 12
Study 21797667 — intervention group
Group type: EXPERIMENTAL
Intervention: Brimonidine 0.1% eye drops twice daily
Number of subjects: 20
Study 21797667 — intervention group
Group type: COMPARATOR
Intervention: Placebo eye drops administered to the other eye twice daily
Number of subjects: 20
Study 19538912 — intervention group
Group type: EXPERIMENTAL
Intervention: University Assistance Program
Number of subjects: 265
Study 19538912 — intervention group
Group type: COMPARATOR
Intervention: Services as usual
Number of subjects: 265
Study 16048742 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise intervention (specific details not provided)
Number of subjects: 82
Study 15100679 — intervention group
Group type: EXPERIMENTAL
Intervention: Inactivated trivalent split-virus influenza vaccine
Number of subjects: 294
Study 15100679 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 294
Study 15100679 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose inhaled corticosteroids (ICS)
Number of subjects: 294
Study 15100679 — intervention group
Group type: EXPERIMENTAL
Intervention: Medium-dose or high-dose inhaled corticosteroids (ICS) or oral corticosteroids
Number of subjects: 294
Study 15100679 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose inhaled corticosteroids (ICS)
Number of subjects: 294
Study 11250990 — intervention group
Group type: EXPERIMENTAL
Intervention: Radical prostatectomy
Number of subjects: 278
Study 11250990 — intervention group
Group type: COMPARATOR
Intervention: External-beam radiotherapy
Number of subjects: 278
Study 11250990 — intervention group
Group type: COMPARATOR
Intervention: Comparison of HRQOL
Number of subjects: 278
Study 9012901 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoflurane (0.5‐1.0 MAC)
Number of subjects: 40
Study 9012901 — intervention group
Group type: COMPARATOR
Intervention: Intravenous sedatives (fentanyl/midazolam)
Number of subjects: 40
Study 8195672 — intervention group
Group type: EXPERIMENTAL
Intervention: 300 U/kg r‐HuEPO on days 1, 4, 7, 10
Number of subjects: 24
Study 8195672 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 U/kg r‐HuEPO on days 1, 5, 9
Number of subjects: 24
Study 8195672 — intervention group
Group type: EXPERIMENTAL
Intervention: 600 U/kg r‐HuEPO on days 1, 10
Number of subjects: 24
Study 3148127 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical mupirocin
Number of subjects: 59
Study 3148127 — intervention group
Group type: COMPARATOR
Intervention: Systemic erythromycin
Number of subjects: 59
Study 31595704 — intervention group
Group type: EXPERIMENTAL
Intervention: Tablet formulation (R)
Number of subjects: 54
Study 31595704 — intervention group
Group type: COMPARATOR
Intervention: Disintegrating tablet formulation (T)
Number of subjects: 54
Study 31595704 — intervention group
Group type: EXPERIMENTAL
Intervention: Both formulations (R and T)
Number of subjects: 54
Study 30722063 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous UAG infusion (1 µg/kg/h)
Number of subjects: 10
Study 30722063 — intervention group
Group type: COMPARATOR
Intervention: Placebo infusion
Number of subjects: 10
Study 27282755 — intervention group
Group type: EXPERIMENTAL
Intervention: Lowered baseline eGFR <70 mL/min per 1.73 m2
Number of subjects: 171536
Study 27282755 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined model of seven risk factors
Number of subjects: 171536
Study 27282755 — intervention group
Group type: EXPERIMENTAL
Intervention: eGFR alone
Number of subjects: 171536
Study 25575896 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous fascia iliaca compartment block (CFICB), n = 25
Number of subjects: 50
Study 25575896 — intervention group
Group type: COMPARATOR
Intervention: Continuous femoral nerve block (CFNB), n = 25
Number of subjects: 50
Study 25575896 — intervention group
Group type: EXPERIMENTAL
Intervention: Comparison of CFICB and CFNB
Number of subjects: 50
Study 23404097 — intervention group
Group type: EXPERIMENTAL
Intervention: Monetary incentives of $100/quarter for viral load suppression
Number of subjects: 80
Study 23404097 — intervention group
Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 80
Study 21689438 — intervention group
Group type: EXPERIMENTAL
Intervention: Asenapine (10 mg twice daily on day 1; 5 or 10 mg twice daily thereafter)
Number of subjects: 977
Study 21689438 — intervention group
Group type: EXPERIMENTAL
Intervention: Asenapine
Number of subjects: 977
Study 21689438 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine (5-20 mg once daily)
Number of subjects: 977
Study 21689438 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 977
Study 19173791 — intervention group
Group type: EXPERIMENTAL
Intervention: Olopatadine 0.2% ophthalmic solution
Number of subjects: 21
Study 19173791 — intervention group
Group type: COMPARATOR
Intervention: Artificial tears (placebo)
Number of subjects: 21
Study 16872952 — intervention group
Group type: EXPERIMENTAL
Intervention: Minimal extracorporeal circulation system
Number of subjects: 20
Study 16872952 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard cardiopulmonary bypass
Number of subjects: 20
Study 16872952 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 20
Study 12555833 — intervention group
Group type: EXPERIMENTAL
Intervention: Alumina ceramic bearings
Number of subjects: 0
Study 10657867 — intervention group
Group type: EXPERIMENTAL
Intervention: Granulocyte colony-stimulating factor (G-CSF)
Number of subjects: 88
Study 10657867 — intervention group
Group type: COMPARATOR
Intervention: No G-CSF (Control)
Number of subjects: 88
Study 9305321 — intervention group
Group type: EXPERIMENTAL
Intervention: 500 mg citicoline
Number of subjects: 259
Study 9305321 — intervention group
Group type: EXPERIMENTAL
Intervention: 2000 mg citicoline
Number of subjects: 259
Study 9305321 — intervention group
Group type: EXPERIMENTAL
Intervention: Citicoline (all doses)
Number of subjects: 259
Study 9305321 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 259
Study 8312736 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine and alcohol intake (heavy users)
Number of subjects: 735
Study 8312736 — intervention group
Group type: COMPARATOR
Intervention: Placebo gum
Number of subjects: 735
Study 3524588 — intervention group
Group type: EXPERIMENTAL
Intervention: Bezafibrate
Number of subjects: 23
Study 28914726 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive behavior therapy for insomnia specific to bipolar disorder (CBTI‐BP)
Number of subjects: 22
Study 28914726 — intervention group
Group type: COMPARATOR
Intervention: Psychoeducation
Number of subjects: 22
Study 27401418 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced Intervention (EI)
Number of subjects: 211
Study 27401418 — intervention group
Group type: COMPARATOR
Intervention: Standard Intervention (SI)
Number of subjects: 211
Study 25379415 — intervention group
Group type: EXPERIMENTAL
Intervention: Dorsal LPFC activity during cognitive control of emotional information
Number of subjects: 23
Study 25379415 — intervention group
Group type: EXPERIMENTAL
Intervention: DLPFC activity during cognitive control of emotional information
Number of subjects: 23
Study 25379415 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 23
Study 22098090 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotic yoghurt (200 g/d for 9 weeks)
Number of subjects: 70
Study 22098090 — intervention group
Group type: COMPARATOR
Intervention: Conventional yoghurt (200 g/d for 9 weeks)
Number of subjects: 70
Study 20484538 — intervention group
Group type: EXPERIMENTAL
Intervention: PEEP ventilation with 5 cm H(2)O (S5)
Number of subjects: 50
Study 20484538 — intervention group
Group type: EXPERIMENTAL
Intervention: PEEP with 10 cm H(2)O (S10)
Number of subjects: 50
Study 20484538 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 degrees Trendelenburg tilt position with PEEP of 0 cm H(2)O (T0)
Number of subjects: 50
Study 20484538 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 degrees Trendelenburg tilt position combined with PEEP of 5 cm H(2)O (T5)
Number of subjects: 50
Study 20484538 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 degrees Trendelenburg tilt position combined with PEEP of 10 cm H(2)O (T10)
Number of subjects: 50
Study 20484538 — intervention group
Group type: COMPARATOR
Intervention: Control condition (S0)
Number of subjects: 50
Study 17287908 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin K2 (MK-4, menatetrenone) 45 mg/day
Number of subjects: 325
Study 17287908 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 325
Study 15962850 — intervention group
Group type: EXPERIMENTAL
Intervention: Fondaparinux
Number of subjects: 0
Study 15962850 — intervention group
Group type: EXPERIMENTAL
Intervention: Melagatran/ximelagatran
Number of subjects: 0
Study 15962850 — intervention group
Group type: COMPARATOR
Intervention: Heparin (implied control)
Number of subjects: 0
Study 12139543 — intervention group
Group type: EXPERIMENTAL
Intervention: nCPAP at 5 cm H2O
Number of subjects: 10
Study 12139543 — intervention group
Group type: EXPERIMENTAL
Intervention: nCPAP at 10 cm H2O
Number of subjects: 10
Study 9459316 — intervention group
Group type: EXPERIMENTAL
Intervention: Very-low-dose warfarin
Number of subjects: 32
Study 9459316 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study 7657419 — intervention group
Group type: EXPERIMENTAL
Intervention: Wash Riding (WR)
Number of subjects: 10
Study 7657419 — intervention group
Group type: COMPARATOR
Intervention: Non-Wash Riding (NWR)
Number of subjects: 10
Study 2650797 — intervention group
Group type: EXPERIMENTAL
Intervention: TP-5 50 mg three times a week for 3 weeks
Number of subjects: 76
Study 2650797 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 76
Study 937989 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise group (23 mothers)
Number of subjects: 103
Study 937989 — intervention group
Group type: COMPARATOR
Intervention: Control group 1 (21 mothers)
Number of subjects: 103
Study 937989 — intervention group
Group type: COMPARATOR
Intervention: Control group 2 (59 mothers)
Number of subjects: 103
Study 31844649 — intervention group
Group type: COMPARATOR
Intervention: Course only (C-group)
Number of subjects: 75
Study 31844649 — intervention group
Group type: EXPERIMENTAL
Intervention: Internship only (I-group)
Number of subjects: 75
Study 31844649 — intervention group
Group type: EXPERIMENTAL
Intervention: Course and internship (CI-group)
Number of subjects: 75
Study 27667025 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 g of l-citrulline and 1 g of l-arginine
Number of subjects: 0
Study 27667025 — intervention group
Group type: COMPARATOR
Intervention: 2 g of l-citrulline or l-arginine
Number of subjects: 0
Study 26695998 — intervention group
Group type: EXPERIMENTAL
Intervention: Apligraf
Number of subjects: 100
Study 26695998 — intervention group
Group type: EXPERIMENTAL
Intervention: EpiFix
Number of subjects: 100